Associate Professor & Research Director, Department of Urology
Case Western Reserve University, USA
Sanjay Gupta is Carter Kissell Associate Professor & Research Director in the Department of Urology at the Case Western Reserve University and at the Urology Institute, University Hospitals Case Medical Center. He holds secondary appointments in the Departments of Nutrition and Division of General Medical Sciences at Case Comprehensive Cancer Center.
Dr Guptas research is primarily on prostate cancer and involves both basic and translational areas of focus. In basic research the focus is to develop appropriate biomarkers for early detection and prognosis of prostate cancer. Another focus is to identify novel targets to monitor the efficacy of treatment with chemopreventive or therapeutic agents. His research interests also include translation of bench research to its application in clinics.
Dr Gupta has authored more than 100 publications, including book chapters, research articles and reviews. His innovative approach to develop these agents in the prevention and treatment of prostate cancer has led to publications in several journals including Cancer Research, Clinical Cancer Research, Oncogene, Proceedings of the National Academy of Sciences, USA, Journal of Clinical Oncology, FASEB Journal and has been featured on NBC-5 news and highlighted in the Plain Dealer, and American Association for Cancer Research press release.
• Molecular mechanism(s) of prostate and bladder carcinogenesis
• Role of inflammation in promoting prostate and bladder cancer
• Biomarker(s) for detection and prognosis of prostate cancer
• Identification and characterization of prostate tumor stem cells
• Epigenetic mechanisms of gene silencing in prostate/bladder cancer and its reactivation by natural agents
• Molecular targets for prevention and treatment of prostate cancer
• Prostate cancer stem cells their characteristics
• Chemoprevention of prostate/bladder cancer by naturally occurring and/or synthetic compounds
• Prevention based clinical trials with promising agents